Biophytis grants Blanver exclusive rights to BIO101 in Latin America in deal
valued at up to EUR108 Million
Biophytis / Key word(s): Miscellaneous/Miscellaneous
Biophytis grants Blanver exclusive rights to BIO101 in Latin
America in deal valued at up to EUR108 Million
20-Jun-2024 / 07:00 CET/CEST
____________________________________________________________
Biophytis grants Blanver exclusive rights to BIO101 in Latin
America in deal valued at up to EUR108 Million
* Biophytis to receive upfront and milestones payments for a
total amount up to EUR108 million, as well as double-digit
royalties on future sales of the product
* Agreement covers commercialization of BIO101 in Latin America
* Biophytis and Blanver intend to collaborate on manufacturing
and joint clinical development for Latin America
Paris (France) and Cambridge (Massachusetts, USA), June, 20th,
2024 - 07:00 am CET - Biophytis SA (Euronext Growth Paris :
ALBPS), ("Biophytis" or the "Company"), a clinical-stage
biotechnology company specialized in the development of
therapeutics for age-related diseases, today announces the
signature of an exclusive license agreement with Blanver, one of
the leading and most trusted pharmaceutical company in Brazil,
for BIO101 (20-Hydroxyecdysone) in Latin American including, but
not limited to Brazil, Mexico, Argentina and Colombia.
The agreement provides that Blanver will be responsible for the
registration, marketing and commercialization of BIO 101
(20-Hydroxyecdysone) in its various indications: obesity,
respiratory infections due to Covid-19, sarcopenia and Duchenne
Muscular Dystrophy (DMD) - once Biophytis has successfully
completed the planned clinical development programmes for its
drug candidate. With 40 years of history, Blanver has become an
expert in infectious diseases, osteoporosis and metabolic
disorders, which is a perfect match with Biophytis. In addition
of Brazil, Blanver has an extensive network of unique
distributors that covers the whole Latin America region.
Under the terms of this partnership, Biophytis will be able to
receive up to EUR108 million including an upfront payment and
further additional payments if certain objectives are achieved.
Biophytis is also eligible to receive double-digit royalties on
net sales of BIO101 (20-Hydroxyecdysone) generated in the
collaboration territory, after obtaining future marketing
authorisations.
This collaboration in one of the main pharma regions in the
world, underscores the potential of BIO101 (20-Hydroxyecdysone)
which is based on the positive clinical results already obtained
in several indications.
Stanislas Veillet, CEO of Biophytis, stated: "I warmly welcome
this new partnership which is a key milestone that will enable
Biophytis to further deploy its strategic roadmap, especially in
obesity. This is a unique opportunity for both companies and
comes at a crucial time as Brazil is the most fast-growing
pharmaceutical market, representing more than $23 billion in
2023. In the LATAM region, 100 million of patients are suffering
from obesity. We look forward to continuing our clinical and
regulatory development work with Blanver over the coming months
and to exploring with them early market access opportunities for
our most advanced indications. Together, we aim to deliver
solutions to patients and physicians over the years ahead."
Sergio Frangioni, CEO of Blanver, commented: "Innovation is part
of the Blanver DNA, and we are thrilled to partner with
Biophytis, to bring this unique medicine in Latin America. We are
very confident that the clinical study of the novel BIO101
(20-hydroxyecdysone), will show encouraging results, which will
support the medical community to obesity, their effects and bring
health and quality of life to so many patients who suffer from
this condition."
* * * *
About BIOPHYTIS
Biophytis SA is a clinical-stage biotechnology company
specializing in the development of drug candidates for
age-related diseases. BIO101 (20-hydroxyecdysone), our lead drug
candidate, is a small molecule in development for muscular
(sarcopenia, phase 3 ready and Duchenne muscular dystrophy),
respiratory (Covid-19 phase 2-3 completed) and metabolic diseases
(obesity, phase 2 to be started). The company is based in Paris,
France, and Cambridge, Massachusetts. The Company's ordinary
shares are listed on Euronext Growth (Ticker: ALBPS -ISIN:
FR0012816825). For more information, visit www.biophytis.com
About BLANVER
Blanver Farmoquímica e Farmacêutica S.A. is a Brazilian company,
founded in 1984, focused on R&D, manufacture and sale of
innovative medicines and active pharmaceutical ingredients
(APIs). The company plays in the segments of HIV, Hepatitis,
Oncology, Hematology and Rare Disease, providing high quality
products for expanding the population's access to medicines
through partnerships with the Ministry of Health and official
laboratories. Blanver is committed in always looking for
innovations that will improve people's health and quality of
life.
Forward-looking statements
This press release contains forward-looking statements.
Forward-looking statements include all statements that are not
historical facts. In some cases, you can identify these
forward-looking statements by the use of words such as
"outlook," "believes," "expects," "potential," "continues,"
"may," "will," "should," "could," "seeks," "predicts,"
"intends," "trends," "plans," "estimates," "anticipates" or the
negative version of these words or other comparable words. Such
forward-looking statements are based on assumptions that
Biophytis considers to be reasonable. However, there can be no
assurance that the statements contained in such forward-looking
statements will be verified, which are subject to various risks
and uncertainties. The forward- looking statements contained in
this press release are also subject to risks not yet known to
Biophytis or not currently considered material by Biophytis.
Accordingly, there are or will be important factors that could
cause actual outcomes or results to differ materially from those
indicated in these statements. Please also refer to the "Risk and
uncertainties the Company is to face» section from the Company's
2023 Financial Report available on BIOPHYTIS website
(www.biophytis.com) and as exposed in the "Risk Factors" section
of form 20-F as well as other forms filed with the SEC
(Securities and Exchange Commission, USA). We undertake no
obligation to publicly update or review any forward-looking
statement, whether as a result of new information, future
developments or otherwise, except as required by law.
Biophytis contacts
Investor relations
Nicolas Fellmann, CFO
Investors@biophytis.com
Pharma partners
Edouard Bieth, CBO
edouard.bieth@biophytis.com
Media
Antoine Denry: antoine.denry@taddeo.fr - +33 6 18 07 83 27
Nizar Berrada: nizar.berrada@taddeo.fr - +33 6 38 31 90 50
Blanver contacts
Investor relations
Sergio José Frangioni, CEO
Media
Herbert Silva: Herbert.silva@blanver.com.br
Lilia Lima de Almeida: lilia.almeida@blanver.com.br
____________________________________________________________
Dissemination of a Financial Wire News, transmitted by EQS Group.
The issuer is solely responsible for the content of this
announcement.
____________________________________________________________
Language: English
Issuer: Biophytis
14 avenue de l´Opéra
75001 Paris
France
Internet: https://www.biophytis.com
ISIN: US09076G1040, FR0012816825
EQS News ID: 1929271
End of Announcement - EQS News Service
____________________________________________________________
1929271 20-Jun-2024 CET/CEST